Related Experiment Video
Updated: Jan 3, 2026
The Use of Mixed Reality in Custom-Made Revision Hip Arthroplasty: A First Case Report
Published on: August 4, 2022
Cementless bipolar hemiarthroplasty in a patient with PMF: a case report
Abdullah A Alturki1, Nayf A Alshammari2, Firas M Alsebayel3
1Department of Orthopedic Surgery, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Abstract:
Myelofibrosis is a myeloproliferative disease that falls under a group of bone marrow malignancies known as myeloproliferative neoplasms. It manifests with splenomegaly, anemia, leukocytosis and, less commonly, bone pain. Ruxolitinib, Janus kinase inhibitor, has been shown to increase survival, to improve symptoms and has the potential to decrease osteosclerotic changes. Herein, we present a case of primary myelofibrosis (PMF) in a 60-year-old female who presented with 8-month history of progressive left hip pain and later was diagnosed with pathological neck of femur fracture that was treated with cementless hemiarthroplasty. In conclusion, the use of cementless implants in hip arthroplasty in the presence of PMF has shown to be an effective and safe choice.
Insights
Primary myelofibrosis (PMF) is a bone marrow malignancy. Cementless hip implants are safe and effective for PMF patients experiencing hip fractures.
Area of Science:
- Hematology
- Orthopedic Surgery
- Oncology
Background:
- Myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow scarring.
- Common symptoms include enlarged spleen, anemia, and leukocytosis.
- Janus kinase inhibitors like Ruxolitinib can improve survival and symptoms.
Observation:
- A 60-year-old female with primary myelofibrosis presented with hip pain and a pathological femur neck fracture.
- The patient underwent cementless hemiarthroplasty for treatment.
Findings:
- The case demonstrates a pathological fracture in a patient with primary myelofibrosis.
- Treatment involved cementless hip arthroplasty.
Implications:
- Cementless implants appear to be a safe and effective option for hip arthroplasty in patients with primary myelofibrosis.
- This approach may improve outcomes for PMF patients with skeletal complications.
